Low Hemoglobin in Head and Neck Cancer: What it Means, Why it Happens, and How it Impacts Care

A low hemoglobin (Hb) level generally indicates anemia, which means the blood carries less oxygen than the body needs; this often causes fatigue, shortness of breath, dizziness, and may necessitate treatment such as transfusion depending on severity. ^{[1] [2]} In people receiving cancer therapy, anemia is common because treatments can reduce red blood cell production or increase losses, and it can sometimes force dose reductions or delays in therapy if symptoms are significant. ^{[1] [3]}

---

What a Low Hemoglobin Level Indicates

• Hemoglobin reflects the oxygen-carrying capacity of red blood cells; when Hb is low, the body must work harder to deliver oxygen, resulting in tiredness, breathlessness, and reduced exercise tolerance. ^{[1] [4]}
• In the oncology setting, a low Hb is usually labeled “anemia” and is a frequent side effect of chemotherapy and radiation. ^{[1] [3]}
• Clinically, anemia can be mild and asymptomatic or severe enough to require interventions such as blood transfusion for symptom relief or to stabilize treatment plans. ^{[3] [2]}

---

Common Causes of Anemia in Head and Neck Cancer

Anemia in head and neck cancer is usually multifactorial, and several mechanisms often overlap:

• Treatment-related marrow suppression: Many chemotherapies suppress bone marrow, lowering red blood cell production; radiation especially at higher doses can also damage marrow reserves. ^{[5] [6]}
• Reduced erythropoietin signaling: Some drugs impair the kidneys’ ability to produce erythropoietin, a hormone that drives red cell production. ^[5]
• Nutritional deficiencies: Low iron, vitamin B12, or folate can limit building blocks for red blood cells, and these deficiencies may be present before or during treatment due to decreased intake, malabsorption, or tumor-related inflammation. ^[7]
• Blood loss: Surgery in highly vascular head and neck regions can cause significant blood loss; mucosal tumors may bleed, and treatment-related mucositis can contribute to occult loss. ^{[6] [8]}
• Chronic disease/inflammation: Cancer-related inflammation can hinder iron utilization and shorten red cell lifespan, contributing to anemia of chronic disease. ^[8]

Symptoms to watch for include unusual fatigue, light-headedness, paleness, chest discomfort, or shortness of breath; reporting these promptly is important because anemia is treatable and sometimes requires urgent attention. ^{[2] [3]}

---

Why Hemoglobin Matters for Treatment and Outcomes

Radiotherapy and Chemoradiation Sensitivity

• Lower pre-treatment hemoglobin has been repeatedly associated with worse local tumor control and overall survival in head and neck cancer treated with radiotherapy or concurrent chemoradiation. ^{[9] [10]}
• In a cohort receiving concurrent cisplatin-based radiochemotherapy, anemic patients had lower 3‑year local control (72% vs 85%) and overall survival (52% vs 77%), and hemoglobin showed a dose–response relationship with outcomes; lower Hb correlated with poorer results. ^[10]
• For early glottic larynx cancer, patients with Hb ≤13 g/dL had markedly lower 2‑year local control and survival compared with those above 13 g/dL, underscoring Hb as a key prognostic factor. ^[9]

The likely biological reason is tumor hypoxia: low Hb reduces oxygen delivery, and hypoxic tumor cells are more resistant to radiation, which relies on oxygen to fix DNA damage. ^{[11] [12]}

Does Correcting Hemoglobin Improve Outcomes?

• Although low Hb is a negative prognostic marker, simply raising Hb with transfusions or erythropoiesis‑stimulating agents (ESAs) has not convincingly improved locoregional control or survival in randomized studies of head and neck radiotherapy. ^{[12] [13]}
• In a randomized trial that transfused patients with “low” Hb to higher targets during radiotherapy, transfusion did not improve locoregional control or survival compared with no transfusion. ^[13]
• ESAs can raise Hb and reduce transfusion needs, but across multiple oncology trials including in head and neck cancer use targeting higher Hb levels was linked with increased thromboembolic risk and, in some studies, worse tumor control and survival; this has led to strict cautions in their use. ^{[14] [15]}
• Product safety information for epoetin formulations highlights decreased locoregional control and survival in head and neck radiotherapy populations when ESAs were used to push Hb into higher ranges, supporting current conservative, risk‑aware practice. ^{[16] [17]}

Taken together, hemoglobin level is a strong prognostic indicator, but aggressive pharmacologic “normalization” to high targets has not proven to improve cancer outcomes and can increase risks. ^{[12] [14]}

---

How Low Hemoglobin Can Affect Treatment Decisions

• Dose modifications or timing: Significant anemia may lead clinicians to adjust chemotherapy doses, delay cycles, or provide supportive care first to reduce symptom burden and safety risks. ^[3]
• Supportive interventions: Depending on symptoms, comorbidities, and Hb level, options may include red blood cell transfusion to rapidly improve oxygen delivery and relieve symptoms. ^[3]
• Careful use of ESAs: ESAs may be considered in selected chemotherapy‑induced anemia when transfusions are unsuitable, using conservative targets and shared decision‑making due to thrombotic and potential tumor‑related risks. ^{[15] [18]}
• Optimize modifiable factors: Correct iron, B12, or folate deficiency when present; address bleeding sources; and ensure adequate nutrition to support erythropoiesis before and during therapy. ^{[7] [6]}
• Smoking cessation: Smoking reduces effective oxygen‑carrying capacity (through carboxyhemoglobin) and is linked with poorer radiotherapy responses; stopping smoking can help improve treatment effectiveness. ^[12]

---

Practical Management Approach

• Identify the cause: A focused workup (iron studies, B12/folate, reticulocyte count, renal function, inflammatory markers, and evaluation for bleeding) helps tailor therapy rather than reflexively transfusing or giving ESAs. ^{[7] [8]}
• Treat the underlying issue: Replace iron (oral or IV), B12, or folate if deficient; control bleeding; and coordinate with the oncology team about timing relative to radiation or chemotherapy. ^{[7] [6]}
• Symptom-guided thresholds: Transfusion is typically considered for symptomatic anemia or very low Hb, with individualized thresholds based on symptoms, comorbidities (e.g., cardiovascular disease), and treatment context. ^[3]
• Monitor closely during treatment: Regular blood counts help anticipate drops in Hb so adjustments can be made early to minimize treatment interruptions and patient discomfort. ^[3]
• Discuss risks and benefits: If ESAs are contemplated for chemotherapy‑associated anemia, discuss thrombosis risk and the lack of proven survival benefit, and avoid targeting high Hb levels. ^{[14] [15]}

---

Key Takeaways

• Low hemoglobin in head and neck cancer generally indicates anemia, most commonly due to treatment effects, nutritional deficiencies, bleeding, or chronic disease processes. ^{[5] [7]}
• Anemia is more than a lab number: it can worsen fatigue and breathlessness, and at lower levels it can interfere with the safe delivery of cancer therapy. ^{[1] [3]}
• Lower pre‑treatment Hb is consistently associated with poorer radiotherapy and chemoradiation outcomes, likely through tumor hypoxia and radioresistance. ^{[10] [9]}
• Simply raising Hb with transfusions or ESAs has not reliably improved cancer control or survival in head and neck radiotherapy, and ESAs carry important safety concerns; management should be individualized and cause‑directed. ^{[13] [12] [14]}

Would you like a simple checklist you can take to your next appointment to discuss anemia testing and management options?